JAGX vs JBIO

Jaguar Health, Inc. vs Jade Biosciences, Inc. — Valuation Comparison 2026

JAGX

Biotechnology
Jaguar Health, Inc.
Quality
4.2
out of 10
Value Trap
47
WARN
Price
$3.29
Last close
Models
5/13
Active
VS

JBIO

Biotechnology
Jade Biosciences, Inc.
Quality
4.1
out of 10
Value Trap
24
SAFE
Price
$20.84
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType JAGX Fair ValueJAGX Upside JBIO Fair ValueJBIO Upside
Bayesian DCF Intrinsic $5.78 -72.3%
First Chicago Scenario $4.44 +27.9% $33.46 +46.1%
ML-RIV Intrinsic $0.66 -90.2% $1.82 -91.3%
Dynamic NAV Asset-Based $3.86 -81.5%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for JAGX vs JBIO — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

JAGX vs JBIO — Which Stock Is More Undervalued?

JAGX scores higher with a 4.2/10 quality rating vs JBIO's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Jaguar Health, Inc. (JAGX) and Jade Biosciences, Inc. (JBIO) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

JAGX currently trades at $3.29 with a QOC of 4.2/10, while JBIO trades at $20.84 with a QOC of 4.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).